4 minutes agoAmazing, cancer vaccines and heart disease very close
Periskopi(3 years ago)
(3 years ago)Millions of lives can be saved by an innovative group of new vaccines for a variety of diseases, including cancer, experts say. One pharmaceutical firm said she is confident that cancer vaccines, cardiovascular and autoimmune diseases and other diseases will be ready by 2030. Studies on these vaccines are also showing [...]
Studies on these vaccines are also showing “extraordinary representation”.
Paul Burton, the leading medical official of the Moderna pharmaceutical company, said he believes the firm will be able to provide such treatments for “all types of disease zones” within five years, Guardian reported.
The firm, which developed a major vaccine against coronarys, is developing cancer vaccines that target various types of tumor.
We will have that vaccine and will be very effective and will save hundreds of thousands, if not millions of lives. I think we will be able to offer personal vaccines against cancer, against various types of tumors for people worldwide”, Burton said.
He also said that multiple respiratory infections can be covered by a single injection by allowing vulnerable people to defend against COVID, flu and cynic respiratory virus (RSV) ) while mRNA therapies may be available for rare diseases for which there are currently no drugs. MRNA - based therapies operate by teaching cells how to make a protein that stimulates the body's immune response to disease.
I think we'll have mRNA-based therapies for rare diseases that were previously inconsistent and I think 10 years from now, we'll be approaching a world where we can really identify the genetic cause of disease and, with relative simplicity, go and modify it and repair it using mRNA” technology, he added.
But scientists warn that accelerated progress, which has increased in the past three years, will be wasted unless a high level of investment is maintained.
First, doctors take a biopsy of a patient's tumor and send it to a laboratory, where its genetic material is listed to identify mutations that are not present in healthy cells.
Then it is identified which of these mutations are responsible for promoting cancer growth. In time, it is also taught which parts of the abnormal proteins that code these mutations are more likely to trigger an immune response. Next, the MRNA for the most promising antigens is produced and packaged into a custom vaccine.
I think what we've learned in recent months is that if you ever thought the mRNA was just for infectious diseases, or just for COVID, the evidence is now that it's not absolutely so”, Burton said.
